
Daniel Catenacci MD
Associate Professor of Medicine, The University of Chicago Medicine, Chicago, IllinoisRecent Contributions to PracticeUpdate:
- FDA Approves Pembrolizumab for Advanced or Metastatic Esophageal/Gastroesophageal Junction Cancer
- Ivosidenib for Patients With IDH1-Mutated Cholangiocarcinoma
- ASCO GI: Adding Lenvatinib to Pembrolizumab in Patients With Advanced Gastric Cancer
- ASCO GI: New Data on FGFR Inhibition With Frontline Bemarituzumab in Gastroesophageal Tumors
- Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications From ATTRACTION-4
- New Data on Adjuvant Treatment of Esophageal Cancer
- Adding Immunotherapy to First-Line Chemotherapy for Esophageal Cancer: Data and Implications From KEYNOTE-590
- Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications From CHECKMATE 649
- Updated Results From an Observational Study of Nivolumab for Advanced Gastric Cancer
- Trastuzumab Deruxtecan for Patients With HER2-Positive Advanced Gastric or GE Junction Adenocarcinoma